1 – 37 of 37
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Comparison of dyskinesia profiles after L-DOPA dose challenges with or without dopamine agonist coadministration
(
- Contribution to journal › Article
- 2020
-
Mark
Preface : The evolving scenario of Parkinson's research
(
- Chapter in Book/Report/Conference proceeding › Foreword/Postscript
-
Mark
Reply to : Letter to Editor by Chaudhuri, Jenner, Antonini
(
- Contribution to journal › Letter
-
Mark
Dyskinesia matters
(
- Contribution to journal › Article
- 2018
-
Mark
Striatonigral neurons divide into two distinct morphological-physiological phenotypes after chronic L-DOPA treatment in parkinsonian rats
(
- Contribution to journal › Article
-
Mark
On the neuronal circuitry mediating l-DOPA-induced dyskinesia
(
- Contribution to journal › Article
-
Mark
mGlu receptors in the treatment of Parkinson's disease and L-DOPA-induced dyskinesia
(
- Contribution to journal › Scientific review
- 2017
-
Mark
Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease
(
- Contribution to journal › Article
-
Mark
Levodopa-induced abnormal involuntary movements correlate with altered permeability of the blood-brain-barrier in the basal ganglia
(
- Contribution to journal › Article
-
Mark
Translating scientific advances into disease-modifying therapies for Parkinson's Disease
(
- Contribution to journal › Article
- 2016
-
Mark
Gene therapy blockade of dorsal striatal p11 improves motor function and dyskinesia in parkinsonian mice.
(
- Contribution to journal › Article
-
Mark
On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats.
(
- Contribution to journal › Letter
- 2015
-
Mark
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease.
(
- Contribution to journal › Scientific review
-
Mark
Zooming in on the small: The plasticity of striatal dendritic spines in l-DOPA-Induced dyskinesia.
(
- Contribution to journal › Article
-
Mark
Rodent models of impulsive compulsive behaviors in Parkinson's disease: how far have we reached?
(
- Contribution to journal › Scientific review
-
Mark
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
(
- Contribution to journal › Article
-
Mark
Increased CSF biomarkers of angiogenesis in Parkinson disease.
(
- Contribution to journal › Article
- 2014
-
Mark
Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism.
(
- Contribution to journal › Article
- 2013
-
Mark
Bad News for Neuroprotective Therapies in PD?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Modulating mGluR5 and 5-HT1A/1B receptors to treat l-DOPA-induced dyskinesia: Effects of combined treatment and possible mechanisms of action.
(
- Contribution to journal › Article
- 2012
-
Mark
A Model of GDNF Gene Therapy in Mice with 6-Hydroxydopamine Lesions: Time Course of Neurorestorative Effects and ERK1/2 Activation
(
- Contribution to journal › Article
- 2011
-
Mark
Parkinson disease: Poor results for retinal cell transplants in Parkinson disease.
(
- Contribution to journal › Article
-
Mark
Putaminal Upregulation of FosB/Delta FosB-Like Immunoreactivity in Parkinson's Disease Patients with Dyskinesia
(
- Contribution to journal › Article
-
Mark
Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.
(
- Contribution to journal › Article
- 2010
-
Mark
Deuterium substitutions in the L-DOPA molecule improve its anti-akinetic potency without increasing dyskinesias
(
- Contribution to journal › Article
-
Mark
Immunohistochemical Detection of Fosb/Delta fosb-Like Proteins Maps Areas of Maladaptive Neuroplasticity in the Post-Mortem Parkinsonian Brain
(
- Contribution to journal › Published meeting abstract
-
Mark
Post- Versus Pre-Synaptic Plasticity
(
- Contribution to journal › Published meeting abstract
-
Mark
Recent advances in Parkinson's disease : basic research. Preface
(
- Contribution to journal › Article
-
Mark
Preface
(
- Chapter in Book/Report/Conference proceeding › Foreword/Postscript
- 2009
-
Mark
Priming for L-DOPA-induced abnormal involuntary movements increases the severity of amphetamine-induced dyskinesia in grafted rats.
(
- Contribution to journal › Article
-
Mark
Plastic effects of L-DOPA treatment in the basal ganglia and their relevance to the development of dyskinesia.
(
- Contribution to journal › Article
- 2007
-
Mark
High dose levodopa therapy is not toxic in multiple system atrophy: Experimental evidence
(
- Contribution to journal › Article
-
Mark
L-DOPA-induced dyskinesia: cellular mechanisms and approaches to treatment.
(
- Contribution to journal › Article
- 2006
-
Mark
On the move to stimulate cell plasticity in the substantia nigra in Parkinson's disease.
(
- Contribution to journal › Letter
- 2005
-
Mark
Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
(
- Contribution to journal › Article
-
Mark
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
(
- Contribution to journal › Article
- 1994
-
Mark
Seizure development and noradrenaline release in kindling epilepsy after noradrenergic reinnervation of the subcortically deafferented hippocampus by superior cervical ganglion or fetal locus coeruleus grafts
(
- Contribution to journal › Article